Back to Search Start Over

Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data

Authors :
Lambertini, Matteo
Moore, Halle C F
Leonard, Robert Cf R.C.F.
Loibl, Sibylle
Munster, Pamela
Bruzzone, Marco
Boni, Luca
Unger, Joseph J.M.
Anderson, Richard Allen
Mehta, Keyur
Minton, Susan
Poggio, Francesca
Albain, Kathy S
Adamson, Douglas D.J.A.
Gerber, Bernd
Cripps, Amy
Bertelli, Gianfilippo
Seiler, Sabine
Ceppi, Marcello
Partridge, Ann A.H.
Del Mastro, Lucia
Lambertini, Matteo
Moore, Halle C F
Leonard, Robert Cf R.C.F.
Loibl, Sibylle
Munster, Pamela
Bruzzone, Marco
Boni, Luca
Unger, Joseph J.M.
Anderson, Richard Allen
Mehta, Keyur
Minton, Susan
Poggio, Francesca
Albain, Kathy S
Adamson, Douglas D.J.A.
Gerber, Bernd
Cripps, Amy
Bertelli, Gianfilippo
Seiler, Sabine
Ceppi, Marcello
Partridge, Ann A.H.
Del Mastro, Lucia
Source :
Journal of clinical oncology, 36 (19
Publication Year :
2018

Abstract

Purpose The role of temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal women remains controversial. This systematic review and meta-analysis using individual patient–level data was conducted to better assess the efficacy and safety of this strategy in patients with early breast cancer. Methods The trials in which premenopausal women with early breast cancer were randomly assigned to receive (neo)adjuvant chemotherapy alone or with concurrent GnRHa were eligible for inclusion. Primary end points were premature ovarian insufficiency (POI) rate and post-treatment pregnancy rate. Disease-free survival and overall survival were secondary end points. Because each study represents a cluster, statistical analyses were performed using a random effects model. Results A total of 873 patients from five trials were included. POI rate was 14.1% in the GnRHa group and 30.9% in the control group (adjusted odds ratio, 0.38; 95% CI, 0.26 to 0.57; P, 001). A total of 37 (10.3%) patients had at least one post-treatment pregnancy in the GnRHa group and 20 (5.5%) in the control group (incidence rate ratio, 1.83; 95% CI, 1.06 to 3.15; P = .030). No significant differences in disease-free survival (adjusted hazard ratio, 1.01; 95% CI, 0.72 to 1.42; P = .999) and overall survival (adjusted hazard ratio, 0.67; 95% CI, 0.42 to 1.06; P = .083) were observed between groups. Conclusion Our findings provide evidence for the efficacy and safety of temporary ovarian suppression with GnRHa during chemotherapy as an available option to reduce the likelihood of chemotherapy-induced POI and potentially improve future fertility in premenopausal patients with early breast cancer.<br />SCOPUS: re.j<br />info:eu-repo/semantics/published

Details

Database :
OAIster
Journal :
Journal of clinical oncology, 36 (19
Notes :
No full-text files, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1081040021
Document Type :
Electronic Resource